KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables - Other: 2018-2024

Historic Receivables - Other for Halozyme Therapeutics (HALO) over the last 4 years, with Dec 2024 value amounting to $20.3 million.

  • Halozyme Therapeutics' Receivables - Other rose 1930.00% to $20.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $20.3 million, marking a year-over-year increase of 1930.00%. This contributed to the annual value of $20.3 million for FY2024, which is 1930.00% up from last year.
  • As of FY2024, Halozyme Therapeutics' Receivables - Other stood at $20.3 million, which was up 1,930.00% from $1.0 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Receivables - Other registered a high of $20.3 million during FY2024, and its lowest value of $1.0 million during FY2023.
  • For the 2-year period, Halozyme Therapeutics' Receivables - Other averaged around $10.7 million, with its median value being $10.7 million (2023).
  • Data for Halozyme Therapeutics' Receivables - Other shows a peak YoY surged of 1,930.00% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Halozyme Therapeutics' Receivables - Other stood at $7.0 million in 2020, then reached $1.0 million in 2023, then skyrocketed by 1,930.00% to $20.3 million in 2024.